Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction: Despite the availability of safe and effective vaccines against Hepatitis B virus (HBV), the infection remains a significant global health issue.This study examined all serological markers of HBV at the largest hospital in İstanbul to identify hepatitis B cases and assess current seroprevalence.Materials and Methods: Data from cases analyzed between May 2020 and October 2023 included the following parameters: hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), antibody to hepatitis B surface antigen (anti-HBs), antibody to hepatitis B e antigen (anti-HBe), IgM antibody to hepatitis B core antigen (anti-HBc IgM), and total antibody to hepatitis B core antigen (anti-HBc total), all measured using the Roche cobas e 801 analyzer.Results: HBsAg positivity was detected in 2.11% of 467,163 patients.Among 39,046 children, the HBsAg positivity rate was 0.47%.The highest HBsAg positivity was observed in the 51-60 age group.Acute hepatitis B, indicated by anti-HBc IgM positivity, was identified in 0.41% of 17,293 patients.Among those who tested positive for HBsAg, 1.90% were also positive for HBeAg.Anti-HBs was positive in 46.27% of 294,631 patients overall and in 67.35% of 44,293 children.The highest anti-HBs positivity was observed in the <1 year and 1-5 year age groups.The lowest positivity rates for both HBsAg and anti-HBs were recorded in 2023.Conclusion: With an HBsAg positivity rate of 2.11%, the region can be classified as having intermediate endemicity.This study aims to support seroprevalence assessments by providing updated data, contributing to efforts toward hepatitis B control goals.Keywords: Hepatitis B virus, acute hepatitis B,
Authors: Mehmet Karabey, Nuran Karabulut, Sema Alacam
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4411001215